Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECAMYLAMINE HYDROCHLORIDE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
FDA: Management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension.,Off-label: Treatment of Tourette syndrome, tics, and as an adjunct in smoking cessation.
Hypertension
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Primarily hepatic with some renal excretion. Metabolized by cytochrome P450 enzymes, likely multiple isoforms, though specific enzymes not fully characterized.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 0-20% bound, primarily to albumin and alpha-1 acid glycoprotein; low binding is clinically insignificant.
~90%, primarily to albumin
Vd approximately 1-2 L/kg; extensive tissue distribution indicates high penetration into tissues.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: approximately 20-50% due to incomplete absorption and first-pass metabolism.
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in patients with renal insufficiency (e GFR <30 m L/min). For mild to moderate impairment, reduce dose by 50% and monitor closely.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and titrate slowly.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for use in children due to lack of safety and efficacy data.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 2.5 mg once daily; increase slowly with careful monitoring due to increased sensitivity to hypotensive effects and higher risk of adverse effects.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None.
None
May cause orthostatic hypotension, syncope, and impaired mental alertness.,Caution in patients with poor renal function, prostatic hypertrophy, or pyloric stenosis.,Risk of rebound hypertension upon abrupt discontinuation.,Mecamylamine may precipitate urinary retention in patients with bladder dysfunction.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to mecamylamine or any component.,Coronary artery disease (risk of precipitation of angina).,Recent myocardial infarction.,Glaucoma (may increase intraocular pressure).,Uremia.,Concurrent use with ganglionic blocking agents.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid excessive alcohol intake as it may potentiate hypotensive effects. No specific food restrictions beyond maintaining a balanced diet.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of teratogenicity due to ganglionic blockade; avoid unless essential. Second/third trimester: may cause fetal hypotension, hypoxia, meconium aspiration, and neonatal respiratory depression due to maternal hypotension and reduced uterine blood flow. Neonatal withdrawal syndrome reported with chronic use.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted in breast milk; M/P ratio not established. Risk of infant ganglionic blockade (hypotension, constipation, urinary retention). Contraindicated in breastfeeding due to potential for serious adverse effects.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No established pregnancy-specific dose adjustments. Use lowest effective dose due to volume of distribution and clearance changes (increased plasma volume, renal clearance). Monitor closely for hypotension; consider dose reduction if significant maternal hypotension occurs.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Mecamylamine is a non-competitive antagonist of nicotinic acetylcholine receptors, used primarily for hypertension. It does not affect parasympathetic ganglia at therapeutic doses. Caution in patients with renal impairment as drug accumulation occurs. Avoid use in patients with glaucoma or pyloric stenosis due to anticholinergic effects.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not skip doses or double up on missed doses.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it can cause dizziness or blurred vision.,Report any signs of slow heart rate, fainting, difficulty urinating, or blurred vision to your healthcare provider immediately.,Do not stop taking this medication abruptly; your blood pressure may rise rapidly.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
"Mecamylamine, a noncompetitive nicotinic acetylcholine receptor antagonist used for hypertension, potentiates the vasodilatory effects of Manidipine, a dihydropyridine calcium channel blocker, by reducing sympathetic reflex responses that normally counteract calcium channel blocker-induced hypotension. This additive hypotensive effect can lead to severe hypotension, dizziness, syncope, and increased risk of falls or cardiovascular events, particularly in elderly patients or those with volume depletion."
"Mecamylamine, a noncompetitive antagonist of nicotinic acetylcholine receptors, blocks sympathetic ganglionic transmission, leading to reduced catecholamine release and hypotension. Phentolamine, a nonselective alpha-adrenergic antagonist, further inhibits vasoconstriction mediated by norepinephrine. Concurrent use results in additive hypotensive effects, increasing the risk of severe hypotension, orthostatic dizziness, and syncope, particularly during initial dosing or dose escalation."
"Mecamylamine, a ganglionic blocker, antagonizes nicotinic acetylcholine receptors, leading to sympatholytic effects. Nabilone, a synthetic cannabinoid, can increase heart rate via central sympathetic activation. The interaction results in Mecamylamine augmenting the tachycardic effects of Nabilone, potentially causing excessive heart rate elevation and risk of cardiac stress."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECAMYLAMINE HYDROCHLORIDE vs ALDORIL 15, answered by our medical review team.
MECAMYLAMINE HYDROCHLORIDE is a Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECAMYLAMINE HYDROCHLORIDE and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECAMYLAMINE HYDROCHLORIDE is: Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECAMYLAMINE HYDROCHLORIDE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECAMYLAMINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of ter. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.